This is the first acquisition by Cytiva since it became a Danaher operating company in April 2020, according to the company. The Vanrx portfolio complements Cytiva's manufacturing capacity solutions, focused on the last critical step before distribution to patients. With a shift toward smaller batches and personalized therapies, companies will need to bring complete bioprocessing workflows in-house, including aseptic filling solutions.

The SA25 Front Operator. Image courtesy of Cytiva.

Vanrx's flagship products -- SA25 Aseptic Filling Workcell and Microcell Vial Filler -- automate aseptic filling using robotics within closed, gloveless isolators. These solutions provide a fast path to a standardized filling capacity as the final step in manufacturing clinical and commercial biopharmaceutics.

"Cytiva becomes the first 'idea to injection' biotechnology company by bringing Vanrx into our already strong portfolio," said Olivier Loeillot, vice president and head of bioprocess at Cytiva. "From drug development, through drug substance and now into drug product, we can help biomanufacturers bring their therapies to patients faster. Vanrx will enhance Cytiva FlexFactory platforms and KUBio modular facilities, enabling us to accelerate biomanufacturing from start to finish."

Cytiva helps Clover scale up biomanufacturing of COVID-19 vaccine
Clover Biopharmaceuticals is working with Cytiva to scale up the company's COVID-19 vaccine manufacturing capabilities.

Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...